In this study, we have evaluated the local versus systemic definite antitumor response after the combined therapeutic antitumor response in tumor-bearing mice subjected to a regimen. We have also compared the effectiveness of combined therapeutic regimen based on the injection of irradiated versus viable tumor vaccines coexpressing the genetically modified Friend erythroleukemia cells (FLC) two genes in the FLC model and in the poorly immunoproducing IFN-␣ and expressing the HSVtk (tk) gene, and genic, metastasizing TS/A adenocarcinoma tumor system. we have investigated the host immune mechanisms Repeated injections of high doses of irradiated IFN-␣-tkinvolved in tumor rejection and development of antitumor expressing tumor cells followed by GCV administration immunity. Repeated subcutaneous (s.c.) injections of resulted in the cure of the majority of mice bearing estabIFNtk-expressing tumor cells, followed by GCV adminislished metastatic tumors, while repeated inoculations of the tration, were effective in counteracting the growth of both same number of viable tumor vaccines were much less contralateral parental tumors as well as visceral metasteffective. We conclude that: (1) IFN-␣ is an essential coases, whereas similar treatments with control tk cells (ie factor in the generation of a systemic antitumor immunity nonproducing IFN) were ineffective. Morphologic analyses following the prodrug-induced tumor cell killing; (2) vacof the homolateral and contralateral tumor tissues and in cines co-expressing an autotoxic gene and a cytokine gene vivo immunosuppression experiments with specific monomay represent promising new tools for the treatment of clonal antibodies revealed that both CD4 + and CD8 + T lymsome cancer patients. phocytes played essential roles in the generation of a Keywords: IFN-␣; cancer gene therapy; HSVtk more pronounced response in the therapy of certain Introduction human cancers. Since the first report on the in vivo behavior of genetically Our laboratory has been especially interested in studymodified mouse tumor cells producing IL-4 in 1989, 1 an ing the mechanisms of the antitumor effect of type I interincreasing number of studies with transduced cells proferon (IFN) in mice and more recently the in vivo behavior ducing different cytokines have been published 2 and of various mouse metastatic tumor cell types producing much attention has been given to the possible clinical murine IFN-␣1. [3] [4] [5] [6] During a set of studies aimed at definapplications for cytokine gene therapy of cancer. As a ing the optimal conditions for achieving complete tumor result of some general enthusiasm in this field, many rejection by using IFN-producing tumor cells, we found clinical trials have been started using genetically modithat the best approach was based on the use of tumor fied tumor vaccines expressing certain cytokines.
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vaccines co-expressing IFN-␣ and an autotoxic gene. 7 Although these experimental and clinical studies have Thus, we have recently reported that peritumoral treatprovided important information on the spectrum of ment with IFN-␣-producing tumor cells expressing the immunological responses potentially induced by cytoHSVtk gene followed by repeated GCV treatments kine-producing vaccines, it is generally assumed that resulted in the long-term tumor eradication and cure of further strategies based on combined therapeutic immunocompetent mice bearing established metastatic approaches should be designed in order to achieve a Friend leukemia cells (FLC) tumors. 7 The success of this combined therapy was based on its ability to induce a potent and long-lasting antitumor immune response, due to a strong synergistic effect between the IFN-␣ locally classic 'bystander effect'. 8 This was indicated by the failwhile only a slight antitumor response was observed when the same treatments were performed with control ure of the combined therapy to eradicate FLC tumors established in immunosuppressed nude mice and by the tk cells not producing IFN-␣. ability of cured immunocompetent animals to resist parental tumor challenge even several months after complete Analysis of the host cells involved in the antitumor response of tumor-bearing mice to the 'IFN-␣-tk/GCV'-eradication of the original tumor. 7 In the present study, we have evaluated the local versus combined regimen We had previously shown that the 'IFN-␣-tk/GCV regisystemic antitumor response in tumor-bearing mice subjected to this combined therapeutic regimen and we have men' did not induce any antitumor effect in splenectomized, irradiated, and anti-asialo-GM 1 -treated nude investigated the host immune mechanisms involved in tumor rejection and development of antitumor immunity.
mice. 7 These data indicated that the mechanisms underlying the therapeutic response to combined therapy were We herein report that repeated s.c. injections of IFNtkexpressing tumor cells, followed by GCV administration, host-mediated. It was of interest, however, to characterize in detail which host mechanisms could be responsible for are very effective in counteracting the growth of both contralateral parental tumors as well as visceral metastthe impressive destruction of the parental tumor after GCV treatment and in particular which host cells could ases, and that both CD4
+ and CD8 + T lymphocytes play an essential role in the generation of a definite antitumor be involved in the generation of the local and systemic antitumor effects. Thus, we performed selective in vivo response after the combined therapeutic regimen. Moreover, the results of some experiments using multiple vacimmunosuppression treatments by using monoclonal antibodies capable of depleting either specific T cell subcine doses indicate that under certain conditions, irradiated cells co-expressing the two genes are even sets (CD4 + or CD8 + cells) or polymorphonuclear cells, in tumor-bearing mice subsequently subjected to the commore effective than their viable counterparts in suppressing tumor growth. These results may provide an bined 'IFN-␣-tk/GCV regimen'. 
Results
tumor response (Table 1 , experiments 1 and 2), thus suggesting that polymorphonuclear cells were also involved in the IFN-␣-tk/GCV-induced destruction of the parLocal and systemic antitumor response in tumor-bearing mice treated with tumor cells co-expressing IFN-␣ and ental tumor. We had previously described the dramatic tumor cell tk Figure 1 shows the representative results of a set of degeneration occurring a few days after GCV treatment in tumor-bearing mice subjected to peritumoral injection experiments in which we evaluated the effectiveness of the genetically modified tumor vaccines co-expressing with tk cells producing IFN. 7 In this study, we have characterized the host cell infiltrates and the tumor cell IFN-␣ and tk when both treatments (ie cells and GCV) were performed either homolaterally or contralaterally in morphology in tumor-bearing mice after the peritumoral or contralateral treatments. Immunohistochemical analymice bearing established FLC tumors.
A single peritumoral injection of 10 7 IFNtk cells folsis of the tumor area in mice receiving the peritumoral injection of IFN-tk-expressing tumor cells and GCV lowed by GCV administration resulted in the complete tumor eradication and cure of the animals (Figure 1a) .
showed the presence of several CD4 + and CD8 + T lymphocytes ( Figure 3b To explore the spectrum of the possible clinical applications of the combined 'IFN-␣-tk/GCV' therapeutic combined therapy was also effective in mice preinjected intravenously (i.v.) with 500 (approximately 50 LD 50 ) strategy further, it was important to determine whether the combination of IFN-␣ and tk genes was also advanmetastatic FLC. As shown in Figure 2 , repeated s.c. injections of IFN-␣-tk cells and GCV resulted in a marked tageous when irradiated (instead of viable) cells were used. In fact, a major concern about the use of viable IFNincrease in survival time as compared with control mice, 
One group of mice was used as a control for 3Cl-8 parental tumor growth and did not receive any further treatment (b). (a) After 3 days, one group of tumor-bearing mice was inoculated peritumorally with 10
7
Cl-11-IFNtk528 cells (̅). Four days later, GCV (150 mg/kg) was administered at the site of tumor growth, twice a day for 5 days. The same schedule of GCV treatment was repeated after a week interval. There were six mice per group. (b) Three days later, one group of tumor-bearing mice was inoculated contralaterally with 10
7 Cl-11IFNtk528 cells (̅) followed by GCV administration as described before. There were six mice per group. P Ͻ 0.
versus 3Cl-8 injected mice. (c) Two groups of mice bearing 3-day tumors received repeated contralateral injections of 10 6 Cl-11-IFNtk528 cells (once a week for 4 weeks). In the first group, consisting of 10 mice, each injection was followed by one cycle of GCV administration (for 4 days, twice a day). The last injection was followed by two 5-day cycles with a week interval (̅). P Ͻ 0.001 versus 3Cl-8 injected mice. In the second group, consisting of six mice, GCV was not administered to the vaccine-treated animals (̆).
␣-tk-expressing tumor cells derived from our previous irradiated versus viable transduced cells, followed by GCV treatments, against the growth of established FLC observation that viable tk tumor cells were not eliminated by GCV in immunosuppressed nude mice. 7 Moreover, in or TS/A adenocarcinoma tumors. In the representative experiment shown in Figure 6a , treatment of mice immunocompetent mice repeatedly injected with high numbers of viable tk cells, GCV did not succeed in totally bearing parental FLC tumors with repeated peritumoral injections of 10 7 irradiated IFN-␣/tk-FLC and GCV suppressing tumor growth of the transduced cells. We then compared the effectiveness of repeated injections of caused complete tumor rejection and cure in 70% of the the best antitumor response was clearly observed in mice also treated with GCV. Only a slight therapeutic effect was observed after repeated injections of irradiated control tk cells (not producing IFN) and GCV, indicating that IFN-␣ secretion was essential for in vivo augmentation of the tk-GCV-induced tumor killing.
Discussion
Genetic transfer of the HSVtk into tumor cells followed by GCV administration has recently received increasing attention as a strategy for selective elimination of cancer cells. Since its first description, 9 the HSVtk/GCVmediated tumor killing has been described in several cancer models including sarcoma, 10 release of the toxic phosphorylated GCV by the tumor cells expressing the HSVtk following GCV-induced killing and its uptake by adjacent unmodified tumor cells via treated animals. On the contrary, when viable IFN-␣/tk cells were used according to the same schedule, there was gap junctions or phagocytosis of apoptotic vesicles. 8, 19, 20 Tumor necrosis consequent to the in vivo tk gene transonly an increase in survival time, but no cure was observed. (Under these conditions, the lack of a definite duction of endothelial cells proliferating at the site of tumor growth and their killing after GCV administration therapeutic response was due to the failure of GCV to eliminate the transduced viable cells, which were repeathas also been indicated as a mechanism potentiating the 'bystander effect'. 15 In these early studies, the particiedly injected.) Very similar results were obtained in mice bearing established poorly immunogenic TS/A tumors pation of the host immune system in the 'bystander effect', as well as its importance in the development and and receiving repeated injections of high doses of irradiated IFN-␣/tk-TS/A cells and GCV (Figure 6b) . maintenance of systemic antitumor immunity was either not taken into consideration or understated. In fact, initial Notably, in both tumor systems, the repeated injections of high numbers of irradiated IFN-␣/tk cells proved observations such as the inability of dexamethasone treatment to diminish the effectiveness of the HSVtk/GCV rather effective even without GCV administration, but DBA/2 mice, 6-7 weeks old, were inoculated s.c. with 2 × 10 6 3Cl-8 cells on day 0 and were left untreated or received a peritumoral injection of 10 7 Cl-11-IFNtk528 cells on day 3, followed by GCV administration starting on day 7, as described in Materials and methods. Antigranulocyte, anti-CD4 or anti-CD8 antibodies were administered i.v. on days 2, 3, 7, 11, 16, 21 and 25. The reported values refer to mice remaining tumor-free when complete rejection of the primary tumor occurred in the group of mice subjected to the combined therapy and not receiving any immunosuppressive treatment (approximately day 40).
Figure 3 Histological and immunohistochemical features of the tumor area in a mouse bearing a 3-day 3Cl-8 parental tumor, subjected to the peritumoral 'IFN-␣/tk/GCV' combined regimen. The Figure shows the pattern observed 7 days after injection of IFN-tk-expressing cells and 3 days since the beginning of GCV administration. (a) Residual tumor cells (arrowheads) are scattered in a fibroadipous tissue with foci of necrosis and several reactive cells; (b, c, d) cryostat sections tested with anti-CD8 (b), anti-CD4 (c), antigranulocyte (d) mAbs, showing several CD8
+ and CD4
+ T lymphocytes and some granulocytes (arrowheads) in the tumor area. (Magnification a-d, × 630).

Figure 4 Histological and ultrastructural features of the parental tumor area after contralateral injection of IFN-producing-tk-expressing tumor cells and GCV treatment. (a) At the edges of the large necrotic area (n), aggregates of severely damaged tumor cells can be observed (× 630); (b) ultrastructural detail of necrotic area constituted by amorphous material, disaggregated cell cytoplasms and naked cell nuclei (arrowheads) (× 3100).
Figure 5 Histological, immunohistochemical and ultrastructural features of the parental 3Cl-8 tumor in a mouse subjected to contralateral 'IFN-␣/tk/GCV' regimen. The Figure shows the pattern observed 18 days after the beginning of combined therapy. (a) Residual aggregates of damaged tumor cells with some reactive cells at the periphery of a large necrotic area (n) (× 630); (b, c) cryostat sections tested with anti-CD4 (b) or anti-CD8 (c) mAbs, showing several CD4 + or CD8 + T lymphocytes in the tumor area (× 630); (d) ultrastructural micrograph showing an area at the periphery of the tumor mass. Amorphous necrotic material is present among residual damaged tumor cells and reactive cells as macrophages (arrows) and lymphocytes (arrowheads) (× 1900); (e) ultrastructural detail of a necrotic area border showing two lymphocytes (arrowheads) close to a tumor cell with a severely damaged cytoplasm (× 3800).
treatments in tumor-bearing rats, 21 or the failure of rats effect', 13 whose magnitude was dramatically reduced in immunodeficient athymic mice, 23 and that a tumor-speimplanted with tk-expressing brain tumor cells and treated with GCV to reject wild-type tumors growing in cific protective immune response developed in animals subjected to the prodrug-induced killing of suicide genethe contralateral hemisphere 16 led to the conclusion that the host immune system was not significantly involved in modified tumor cells. 24, 25 In particular, the study by Barba and colleagues 25 emphasized the crucial importance of tk/GCV-mediated tumor regression. Subsequent studies, however, pointed out the limited and variable efficacy of antitumor immune mechanisms in suppressing the outgrowth of residual tumor cells after tk/GCV treatments. the HSV/tk-GCV autotoxic system, depending on several factors, including efficiency of transduction, 15 immunoHowever, the development of a protective immune response occurred incidentally (only in some of the logic characteristics of different tumors as well as the state of the tumor cells with respect to the phase of the treated animals), suggesting that additional mechanisms, secondary to the tk/GCV tumor cell killing, must occur in cell cycle during GCV administration, 11 and extent of gap junctions. 22 Moreover, some of these studies indicated order to sustain long-term tumor regression. From these results, it could be inferred that a more potent and longthat immune components participated in the 'bystander 
.60tk cells (once a week for 4 weeks), either irradiated () or viable (̅). Each injection was followed by a 4-day cycle of GCV administration. The last injection was followed by two 5-day cycles with a week interval. The same schedule was used for the group injected with irradiated 3Cl-8tk122 or I/A.TCtk cells (̆). Another group of mice was injected with irradiated Cl-11-IFNtk528 or I/A.4.60tk cells but did not receive GCV (). One group of mice was used as a control for 3Cl-8 or TS/A parental tumor growth and did not receive any further treatment (b). There were six mice per group.
term antitumor response to the tk/GCV regimen could autotoxic gene (tk) and a cytokine gene (ie IFN-␣1). 7 In the present study, we have investigated the mechanisms be achieved by combining this approach with cytokinegene therapy, since some immunoregulatory cytokines of the potent antitumor response generated after this combined therapy. We have shown that repeated injecare capable of converting a local response into a systemic antitumor immune response, particularly important for tions of tumor cells expressing tk and producing IFN-␣ followed by GCV treatments are effective in inhibiting those tumors showing a poor bystander effect and especially for metastatic cancers.
subcutaneous tumors growing at distant sites as well as visceral metastases. Our data indicate that the generation Very little information is available on the therapeutic efficacy of the combination of cytokine genes and cytoof an effective systemic antitumor response strictly requires both the IFN-producing phenotype of the tk cells toxic genes and apparently conflicting results have been obtained, depending on the tumor model or the site of and GCV administration. Notably, the morphological and immunohistochemical analysis of the parental tumor tumor injection. In one case, the in situ transduction of previously implanted rat brain tumors with retroviral area revealed zones of ischemic necrosis and the presence of infiltrating CD4 + and CD8 + T lymphocytes and macrovectors expressing both interleukin-2 (IL-2) and tk genes did not result in any enhancement of tumor eradication phages in mice subjected to contralateral injections of IFN-␣-tk-expressing tumor cells and GCV, similar to compared with the transduction with the vector carrying the tk gene alone. 21 However, IL-2 transduction of the what was observed after peritumoral treatment. This observation further supports the notion that the host same glioma cells implanted s.c. caused a potent inhibition of their growth, suggesting that the brain localizimmune response elicited locally by the combined therapy is nevertheless capable of acting systemically against ation of the tumor was an obstacle to the development of an immune antitumor response. 21 A more recent report 26 distantly growing tumors. Interestingly, the RT-PCR analysis of the cytokine expression at the site of tumor showed that intratumoral administration in established hepatic metastases of adenoviral vectors carrying the growth indicated that a consistent increase in the level of IFN-␥ mRNA, among all the cytokine mRNAs analyzed HSVtk and mouse IL-2 genes, followed by GCV treatments, resulted in a significant antitumor response; how-(TNF-␣, TNF-␤, IL-1␤, IL-2, IL-10, IL-4, IL-12, IFN-␥), occurred after the peritumoral injection of Cl-11tk528 ever, no definite cure of the injected animals was observed. A similar short-term antitumor response was cells (data not shown). The main role played by both CD4 + and CD8 + T lymphocytes in determining the sucobserved in a murine model for oral cancer. 27 Very recently, using a different murine model for hepatic metcessful outcome of the 'IFN-␣/tk/GCV' therapy is clearly demonstrated by the lack of response to the combined astases of colon carcinoma, the same authors described how the combination of adeno-tk and adeno-IL-2 with a therapy in mice depleted of these lymphocyte populations. Thus, taking into consideration the data third adenoviral vector carrying the mouse granulocytemacrophage colony-stimulating factor (mGM-CSF) presented in this article as well as in previous studies, 6, 7 the following kinetics of events can be envisaged: (1) the potentiated the antitumor immunity and resulted in the long-term survival of a significant proportion of the injection of IFN-␣-producing tumor cells into tumorbearing mice may rapidly cause the recruitment of a treated animals. 28 We have recently described the first example of an prominent infiltrate of macrophages, neutrophils and lymphocytes within the parental tumor tissue as well as effective therapy of tumor-bearing mice by means of genetically modified tumor vaccines coexpressing both an the appearance of initial areas of tumor cell degeneration, possibly caused by secondary factors released by the indicating that the injection of irradiated HSVtk genemodified human colon carcinoma cells followed by GCV infiltrating cells; (2) these early events are likely to create the conditions (through the recruitment of antigentreatments could prolong the survival of mice bearing intraperitoneal syngeneic fibrosarcomas. 34 The authors presenting cells, activation of some immune effector cells and continuous production of cytokines) for the generconcluded that irradiated xenogeneic tk-expressing tumor cells could generate a potent 'bystander effect' in vivo, ation of an initial antitumor immune response; (3) after GCV treatment, the massive tumor cell destruction may enhanced by immunostimulation caused by the release of inflammatory cytokines. 34 Regarding the perspectives induce further functional interactions between tumor antigens and host reactive cells, thus resulting in the conof further clinical studies, our results indicate that a direct combination of a cytokine gene with an autotoxic gene in version of a local reaction into a systemic response, which is definitively mediated by immune T lymphocytes.
a tumor vaccine could result in a much more impressive antitumor response and in the development of both local In this article, we have also compared the effectiveness of irradiated versus viable tumor vaccines co-expressing and systemic antitumor immunity. Several clinical trials with genetically modified tumor the two genes. This issue is of particular importance, especially because of the concerns regarding the risk of cells producing various cytokines are currently under way. Recently, however, the initial enthusiasm which using viable tumor vaccines in cancer patients. In fact, the use of any viable tumor vaccine expressing an autoaccompanied the start of these clinical studies has been replaced by the focus of attention on the development of toxic gene still poses the fundamental issue of the safety of the transduced tumor cells, which could persist after new and more effective strategies in the preparation of cancer vaccines. Although we do not know the potential prodrug administration, especially when injected repeatedly in high numbers and in patients whose immune syseffectiveness of combining other cytokine genes with the HSVtk/GCV system, IFN-␣ is a good candidate for this tem may be somehow impaired. Our results clearly indicate that: (1) repeated injections of high doses of type of tumor vaccine strategy. IFN-␣ was the first cytokine to be used clinically for the treatment of some maligirradiated IFN␣-tk-expressing tumor cells are more effective and safer than their viable counterparts for the treatnancies and extensive information is now available on its role in the generation and action of immune T lymphoment of mice bearing established metastatic tumors; (2) both IFN␣ production by the tumor cells and their cell cytes. 35 The importance of IFN-␣ for the generation of a protective antitumor immunity has been demonstrated in death induced by GCV are necessary prerequisites for achieving an optimal antitumor response. These results several experimental models. 35 It may be worth noting that some human cancers in which IFN-␣ is somehow were obtained using two unrelated tumors (ie FLC and TS/A), which show marked differences in their origin, effective (ie melanoma, ovarian carcinoma, renal cell cancer) are those in which the development of an antipattern of in vivo growth and immunogenicity. In particular, it is worth mentioning that these tumors also exhitumor immune response is considered to be important. Nevertheless, the use of IFN-␣ in cancer gene therapy bit marked differences in their response to the tk-GCVinduced tumor killing per se. In fact, while a single perituprotocols has not yet been taken into consideration. We thus conclude that: (1) IFN-␣ is an interesting cytokine moral injection of tk-expressing cells (not producing IFN) followed by GCV treatment only resulted in a slight antito be considered in cytokine gene therapy of cancer; (2) vaccines co-expressing an autotoxic gene and a cytokine tumor response in the FLC system, 7 the same treatment regimen induced a remarkable tumor rejection in the gene may represent promising new tools for the treatment of some cancer patients. TS/A model (our unpublished results). Nevertheless, in both models, an optimal antitumor response was always found when tumor-bearing mice were injected with Materials and methods tumor cells co-expressing the two genes (IFN-␣ and tk). FLC and TS/A represent aggressive tumor models and Mice 3-day-old 3Cl-8 or TS/A s.c. tumors can be considered Male DBA/2 mice, 6-7 weeks old were purchased from established tumors on the basis of previous obserCharles River Breeding Laboratories (Italia Calco, Italy). vations.
29-32
Nevertheless, further experiments are needed to evaluate the therapeutic potential of the combined regimen against more advanced primary Tumor cells 3Cl-8, an IFN-␣/␤-resistant clone of FLC passaged in tumors or metastases, by increasing the dose or the number of injections of the irradiated vaccine. These experivitro, was originally obtained from Dr E Affabris. 36 The cells were subsequently passaged in vivo by weekly i.p. mentswill help to define the relevance of the 'IFN-␣/tk/GCV' combination therapy to the treatment of injections into DBA/2 mice. These in vivo passaged 3Cl-8 FLC were highly metastatic for the liver and the human malignancies.
The observation that repeated treatments with spleen. 29 TS/A is a highly aggressive and metastasizing cell line established from the first in vivo transplant of a irradiated IFN-␣-tk-expressing tumor cells followed by GCV administration result in the cure of the vast majority moderately differentiated mammary adenocarcinoma that arose spontaneously in a 20-month-old multiparous of mice bearing established metastatic tumors strongly supports the possibility of using irradiated tumor cells BALB/c mouse. 30 The minimal 100% TS/A parental cells (TS/A-pc) tumor-inducing dose is 4 × 10 4 cells in synexpressing both a cytokine and an autotoxic gene for the development of more effective and safe cancer vaccines.
geneic BALB/c mice. The Cl-11tk528 and the I/A.4.60tk clone were obtained after transfection of the IFN-producRecently, the clinical use of allogeneic irradiated tk-positive ovarian cancer cells has been proposed for the treating FLC clone IFN-␣1-Cl-11 3 and TS/A clone I/A.4.60, 4 respectively, with the tgCMV/HyTK plasmid containing ment of patients with ovarian cancer. 33 The rationale of this clinical protocol was based on previous results a hygromycin phosphotransferase-thymidine kinase fusion gene as previously described. 7 Cl-11tk528 and were removed by washing, and the slides were incubated with ABC complex/AP (Dako, Glostrup, Denmark). I/A.4.60tk cells secreted about 500 and 60 IU/ml of IFN-␣, respectively. The 3Cl-8tk122 and TS/Atk clones, obtained after transfection of 3Cl-8 parental FLC and Statistical analysis TS/A-pc with the tgCMV/HyTK plasmid, were used as Data were analyzed by Wilcoxon's sum rank test. controls for the potential effects of vector sequences. The susceptibility to the cytotoxic action of GCV in vitro as well as in vivo was previously demonstrated for both Cl-
